Pyelonephritis — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Infection and swelling of the kidney and renal pelvis are called pyelonephritis. Pyelonephritis is a potentially catastrophic complication of transplantation. Pyelonephritis can result in graft loss and manifest as acute renal failure. Based on a single series, 80% of bouts of pyelonephritis occur a year or more after transplantation, with E. Coli being the most prevalent pathogen in 80% of cases. When pyuria is present, flank discomfort and soreness strongly suggest pyelonephritis and help to distinguish it from other UTIs. Every patient should have a urine culture and antimicrobial susceptibility testing; if clinically appropriate, the urine culture should be completed before the patient receives antibiotics. A significant inflammatory response to renal parenchymal infection in pyelonephritis leads to swelling that modifies normal tissue characteristics and efficiency. A urinalysis and culture with sensitivity testing are necessary for all patients with suspected pyelonephritis. Outpatient therapy is appropriate for patients with a mild infection who do not have a fever or other systemic symptoms. Any patient who meets the criteria for a complex infection (such as those who are immunocompromised, have urinary tract anomalies, or have an infection related to urologic surgery) or who might not comply should be admitted, as should all other patients. deliver radiologic contrast agent to the location, causing uptake on a nuclear cortex scan.
- Acute pyelonephritis in the US is estimated to be at a rate of 15 to 17 cases per 10,000 females and 3 to 4 cases per 10,000 males per year.
Thelansis’s “Pyelonephritis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pyelonephritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Pyelonephritis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Pyelonephritis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
